Quarterly ResultMay 15, 2026, 07:52 AM
Galectin Therapeutics Q1 Net Loss $(5.05M); R&D down 65.6%
AI Summary
Galectin Therapeutics reported a net loss of $(5.05) million for the three months ended March 31, 2026, a significant improvement from $(9.63) million in the prior year. This was primarily driven by a 65.6% reduction in research and development expenses. The company's cash and cash equivalents stood at $14.11 million, and it anticipates sufficient liquidity to fund operations through May 2027, including a $10 million line of credit. Additionally, the maturity dates for several convertible notes and lines of credit with a related party were extended to June 30, 2027.
Key Highlights
- Net loss decreased by 47.6% to $(5.05) million for Q1 2026.
- Research and development expenses fell 65.6% to $2.23 million.
- Cash and cash equivalents were $14.11 million as of March 31, 2026.
- Net cash used in operating activities improved by 49.7% to $(3.87) million.
- Convertible notes payable maturity extended to June 30, 2027.
- Convertible line of credit maturity extended to June 30, 2027.
- Company expects to fund operations through May 2027.
Price Impact
More from GALT